Baird Medical Investment Holdings Limited (BDMD) AI Stock Analysis

Baird Medical Investment Holdings Limited, founded in 2012 and based in Guangzhou, China, researches, develops, manufactures, and sells microwave ablation and other medical devices in the People's Republic of China. The company provides microwave ablation apparatus and needles, including long and fine needles used for soft tissue ablation and treating benign and malignant tumors such as thyroid nodules, liver cancer, lung cancer, breast lumps, and uterine fibroids. Baird Medical sells its products through third-party distributors. Additionally, the company maintains a strategic cooperation agreement with Tianjin Yuanshan Medical Technology Co., Ltd. focused on the global development and commercialization of next-generation IRE technologies.

Revenue declined 39.2% in FY2025 to $22.5M after growing 17.7% to $37.0M in FY2024. Over the five years from FY2020 to FY2025, revenue grew at a CAGR of 4.5%. While gross margin stayed elevated at 83.8% in FY2025, operating margin fell to -113.3% and net income dropped to -$27.3M, pressured by $20.1M in research and development expenses compared to $6.2M in FY2024. For the trailing twelve months ended June 30, 2026, revenue stood at $24.5M with an operating margin of 8.5% and a profit margin of -65.1%. In the latest quarter ended June 30, 2026, quarterly revenue increased 24.6% year-over-year, while quarterly earnings growth fell 0.3%.

As of June 30, 2026, Baird Medical held $289,083 in cash and short-term investments against total debt of $14.2M, resulting in net debt of $13.9M. Total assets were $73.8M against shareholders' equity of $34.8M, yielding a debt-to-equity ratio of 0.41 and a current ratio of 1.29. Cash flow has remained negative, with operating cash flow at -$1.3M and free cash flow at -$1.4M in FY2025. Capital expenditures totaled $42,315 for FY2025.

At $0.57 per share, Baird Medical carries a market capitalization of $18.2M and an enterprise value of $39.2M. The stock trades at a forward P/E of 5.6x, well below the 17.3x median of its US-listed Healthcare peers. Its price-to-sales ratio of 0.7x also trades below the peer median of 4.1x, while its EV-to-EBITDA stands at 133.6x compared to the peer median of 12.0x. Over the past year, BDMD fell 63.5%, significantly lagging the S&P 500 return of 16.8%.

One analyst covering Baird Medical projects next fiscal year revenue of $32.5M, representing 18.3% growth, and EPS of $0.14, representing 75.0% growth. For the current fiscal year ending December 31, 2026, consensus estimates target revenue of $27.5M and EPS of $0.08. The mean price target is $4.00, implying 606.7% upside above the last close of $0.57. Over the last four quarters, the company beat EPS estimates 2 times.

This page is an AI-written research summary of Baird Medical Investment Holdings Limited (BDMD). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: BDMD income statement, BDMD balance sheet, BDMD key metrics, BDMD analyst forecast, BDMD chart. See the BDMD stock overview for the latest quote and news.